Document is current
Any future updates will be listed below
-
Authors
Kaneko, Yutaro http://orcid.org/0000-0002-2566-7229
Hatano, Ryo
Hirota, Naoto
Isambert, Nicolas
Trillet-Lenoir, Véronique
You, Benoit
Alexandre, Jérôme
Zalcman, Gérard
Valleix, Fanny
Podoll, Thomas
Umezawa, Yoshimi
Takao, Seiichi
Iwata, Satoshi
Hosono, Osamu
Taguchi, Tetsuo
Yamada, Taketo
Dang, Nam H.
Ohnuma, Kei
Angevin, Eric
Morimoto, Chikao
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP20H03471, JP18H02782, JP20K07683)
Ministry of Health, Labour and Welfare (180101-01)
- License Information
-
More Information
Article History
Received: 9 December 2020
Accepted: 10 March 2021
First Online: 23 March 2021
Declarations
:
: All patients provided written informed consent. This study was conducted according to the Declaration of Helsinki and was approved by ethics committees and the French National Drug Agency.
: Not applicable.
: Yutaro Kaneko is a chief executive officer of Y’s AC Co., Ltd., Japan, Thomas Podoll is an employer of Y’s Therapeutics Inc., USA, and Chikao Morimoto, Kei Ohnuma, Nam H. Dang and Taketo Yamada are stock holders of Y’s AC Co., Ltd. Other authors declare no conflict of interest.
